Dr. Kim R50 Research Specialist Clinician 2022

Kim 博士 R50 研究专家临床医生 2022

• 批准号: 10569298
• 负责人: Michelle Miran Kim
• 金额: $ 17.17万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-10 至 2028-02-29
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10569298
• 关键词: Address; Award; Awareness; Brain Neoplasms; Cancer Center; Clinical Research; Clinical Trials; Collaborations; Communities; Community Clinical Oncology Program; Development; Disease; Eligibility Determination; Event; Funding; Glioblastoma; Guidelines; Infrastructure; Institution; Interest Group; Intervention; Intervention Trial; Journals; Lead; Leadership; Malignant neoplasm of central nervous system; Metastatic Neoplasm to the Central Nervous System; Metastatic malignant neoplasm to brain; Michigan; Minority; Mission; National Comprehensive Cancer Network; Newsletter; Oncology; Patients; Phase; Phase II/III Trial; Population; Principal Investigator; Process; Protocols documentation; Radiation therapy; Research; Research Personnel; Research Support; Review Committee; Site; Specialist; United States National Institutes of Health; Universities; Woman; Work; imaging biomarker; inter-institutional; investigator-initiated trial; medical specialties; member; neuro-oncology; participant enrollment; patient population; programs; screening program; trial enrollment; tumor; virtual

Abstract Dr. Kim is an active and vital leader in the clinical trials program at The University of Michigan Rogel Cancer Center whose extensive, collaborative work has supported the NCI clinical trials infrastructure institutionally and nationally. Her key contributions to the mission and conduct of NCI-sponsored clinical trials include: 1) Institutional leadership of the Cancer Center Neuro-Oncology clinical research group and institutional Protocol Review Committee; 2) Serving as site Principal Investigator and central study team member for NCI-funded clinical trials; 3) National leadership as Co-Chair of the NIH/NCI Brain Metastases Interest Group and active member of NRG and Alliance Brain Tumor Committees; 4) National leadership in implementing practice- changing findings from NCI-funded clinical trials as member of the NCCN Guidelines CNS Cancers Committee and Senior Associate Editor of her specialty’s primary journal. Dr. Kim is an active investigator who has contributed 165 patient enrollments to interventional treatment and non-treatment (supportive and observational) trials since 2015, and has served as Principal Investigator of 5 investigator-initiated studies which she has developed and conducted. A recently completed trial is now in development as a multi-site study through the NRG Brain Tumor Committee. She has helped lead institutional and national efforts to broaden trial eligibility for underrepresented demographic and disease populations. Through the support of the Research Specialist Award, Dr. Kim proposes to advance the institutional clinical research mission, and to establish her research and national leadership contribution to NCI funded clinical trials. To address the Cancer Center’s objectives to increase accrual to interventional trials overall, and to increase institutional accrual of minorities and women, Dr. Kim proposes to launch a screening program across the entire Cancer Center to identify and enroll trial-eligible patients for CNS metastases-related trials (NCI-funded trials which have had suboptimal accrual). To expand the catchment of a more diverse patient population from the broader oncology community, she proposes to partner with University of Michigan affiliated community sites to develop streamlined processes for multi-site collaboration, launch a University of Michigan Network virtual tumor board to discuss cases and trial options, distribute newsletters and conduct CME events to increase awareness and participation in NCI-funded and investigator-initiated trials. She will finalize and conduct as Principal Investigator the initial phase of a developing Phase II/III Trial through NRG Oncology investigating an imaging biomarker to personalize radiotherapy in patients with glioblastoma. She will facilitate new inter-institutional collaborations and launch research initiatives as Co-Chair of the NIH/NCI Brain Metastases Interest Group, and will further advance in her participation and national leadership in support of NCI-funded clinical research.

摘要 博士Kim是密歇根大学Rogel Cancer临床试验项目的积极和重要领导者 中心，其广泛的合作工作在制度上支持了NCI临床试验基础设施 以及全国范围内。她对NCI申办的临床试验的使命和实施的主要贡献包括：1） 癌症中心神经肿瘤学临床研究组的机构领导和机构方案 审查委员会; 2）担任研究中心主要研究者和NCI-Funded中心研究团队成员 临床试验; 3）作为NIH/NCI脑转移兴趣小组的联合主席， NRG和联盟脑肿瘤委员会的成员; 4）在实施实践中的国家领导- 作为NCCN指南CNS癌症委员会的成员， 她的专业主要期刊的高级副主编金博士是一名活跃的调查员， 有165例患者入组介入治疗和非治疗（支持性和 自2015年以来，他一直担任5项药物启动研究的主要研究者 是她自己设计和指挥的最近完成的一项试验目前正在开发一个多地点试验， 通过NRG脑肿瘤委员会进行研究。她帮助领导了机构和国家的努力， 扩大代表性不足的人口统计学和疾病人群的试验资格。通过支持， 研究专家奖，金博士建议推进机构临床研究使命，并 建立她的研究和国家领导贡献NCI资助的临床试验。为了解决癌症 中心的目标是增加总体干预性试验的应计费用，并增加机构的 少数民族和妇女，金博士建议在整个癌症中心启动一项筛查计划， 确定并招募符合试验条件的患者进行CNS疾病相关试验（NCI-funded trials which have 次优应计）。从更广泛的肿瘤学中扩大更多样化患者人群的覆盖范围 社区，她建议与密歇根大学附属社区网站合作， 简化多站点协作流程，启动密歇根大学网络虚拟肿瘤委员会 讨论病例和试验方案，分发通讯并开展继续医学教育活动，以提高认识， 参与国家癌症研究所资助的和制药商发起的试验。她将最终确定并作为校长 通过NRG Oncology研究成像，研究正在进行的II/III期试验的初始阶段 生物标志物，使胶质母细胞瘤患者的放射治疗个性化。她将促进新的机构间 作为NIH/NCI脑转移兴趣小组的联合主席， 并将进一步推动她的参与和国家领导，以支持NCI资助的临床研究。